Fluorouracil

Generic Name: Fluorouracil

Brand Names: Actikerall, Carac, Efudex, Fluoroplex, Tolak

Drug Type: Small Molecule

Chemical Formula: C_₄H_₃FN_₂O_₂

CAS Number: 51-21-8

Unique Ingredient Identifier: U3P01618RT

Background: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid.

Indication: For the topical treatment of multiple actinic or solar keratoses. In the 5% strength it is also useful in the treatment of superficial basal cell carcinomas when conventional methods are impractical, such as with multiple lesions or difficult treatment sites. Fluorouracil injection is indicated in the palliative management of some types of cancer, including colon, esophageal, gastric, rectum, breast, biliary tract, stomach, head and neck, cervical, pancreas, renal cell, and carcinoid.

Associated Conditions: Actinic Keratosis (AK), Breast Cancer, Colon Cancer, Gastric Cancer, Pancreatic Cancer, Rectal Cancer, Superficial Basal Cell Carcinoma, Verruca (Warts), Hyperkeratotic actinic keratosis

Associated Therapies: -

Clinical Trials

A Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Participants With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723)

Phase 1

Completed

Conditions: Solid Tumor

Interventions: Drug: Epacadostat
Drug: Pembrolizumab
Drug: Oxaliplatin
Drug: Gemcitabine
Drug: Pemetrexed
Drug: Cyclophosphamide
Drug: nab-Paclitaxel
Drug: Carboplatin
Drug: Paclitaxel
Drug: Leucovorin
Drug: 5-Fluorouracil
Drug: Cisplatin
Drug: Investigator's choice of platinum agent

First Posted Date: 2017-03-21

Last Posted Date: 2022-09-23

Lead Sponsor: Incyte Corporation

Target Recruit Count: 70

Registration Number: NCT03085914

Locations: 🇺🇸
The Angeles Clinic and Research Institute, Los Angeles, California, United States
🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Mayo Clinic Arizona, Phoenix, Arizona, United States

and more 12 locations

Hypofractionated Stereotactic Body Radiation & Fluorouracil or Capecitabine for Locally Advanced Pancreatic Cancer

Phase 2

Recruiting

Conditions: Stage III Pancreatic Cancer AJCC v6 and v7
Pancreatic Adenocarcinoma
Stage IB Pancreatic Cancer AJCC v6 and v7
Stage IIA Pancreatic Cancer AJCC v6 and v7
Recurrent Pancreatic Carcinoma
Stage I Pancreatic Cancer AJCC v6 and v7
Stage IA Pancreatic Cancer AJCC v6 and v7
Stage IV Pancreatic Cancer AJCC v6 and v7
Stage II Pancreatic Cancer AJCC v6 and v7
Stage IIB Pancreatic Cancer AJCC v6 and v7

Interventions: Drug: Capecitabine
Drug: Fluorouracil
Other: Laboratory Biomarker Analysis
Other: Pharmacological Study
Radiation: Stereotactic Body Radiation Therapy
Drug: Zoledronic Acid

First Posted Date: 2017-03-08

Last Posted Date: 2024-01-05

Lead Sponsor: University of Nebraska

Target Recruit Count: 44

Registration Number: NCT03073785

Locations: 🇺🇸
University of Nebraska Medical Center, Omaha, Nebraska, United States

Study of Chemotherapy With or Without Hepatic Arterial Infusion for Patients With Unresectable Metastatic Colorectal Cancer to the Liver

Phase 2

Withdrawn

Conditions: Colorectal Adenocarcinoma Metastatic to the Liver

Interventions: Drug: Floxuridine (FUDR)
Drug: Irinotecan (CPT-11)
Drug: FLUOROURACIL
Drug: PANITUMUMAB
Drug: DEXAMETHASONE
Drug: Leucovorin

First Posted Date: 2017-03-03

Last Posted Date: 2019-05-21

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Registration Number: NCT03069950

Locations: 🇺🇸
Memorial Sloan Kettering Commack, Commack, New York, United States
🇺🇸
Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States
🇺🇸
Memoral Sloan Kettering Westchester, Harrison, New York, United States

and more 2 locations

Standard of Care Alone or in Combination With Ad-CEA Vaccine and Avelumab in People With Previously Untreated Metastatic Colorectal Cancer QUILT-2.004

Phase 2

Terminated

Conditions: Colorectal Tumors
Colorectal Neoplasms
Colorectal Cancer
Colorectal Carcinoma
Colorectal Adenocarcinoma

Interventions: Drug: Bevacizumab
Drug: Avelumab
Drug: 5-Fluorouracil (FU)
Biological: Ad-CEA vaccine
Drug: Leucovorin
Drug: Oxaliplatin
Drug: Capecitabine

First Posted Date: 2017-02-13

Last Posted Date: 2021-12-20

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 30

Registration Number: NCT03050814

Locations: 🇺🇸
Lombardi Comprehensive Cancer Center, Washington, District of Columbia, United States
🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

mFOLFOX Versus mFOLFIRI Versus FOLFPTX as First-line Treatment in AGC or EGJA

Not Applicable

Conditions: Advanced Gastric Cancer Adenocarcinoma of Esophagogastric Junction

Interventions: Drug: Fluorouracil
Drug: Irinotecan
Drug: Oxaliplatin
Drug: Paclitaxel
Drug: calcium levofolinate

First Posted Date: 2017-02-07

Last Posted Date: 2017-02-07

Lead Sponsor: Fujian Cancer Hospital

Target Recruit Count: 150

Registration Number: NCT03045770

Locations: 🇨🇳
Jianwei Yang, Fuzhou, Fujian, China

Nal-IRI and 5-FU Compared to 5-FU in Patients With Cholangio- and Gallbladder Carcinoma Previously Treated With Gemcitabine-based Therapies

Phase 2

Completed

Conditions: Cholangiocarcinoma Non-resectable
Cholangiocarcinoma Metastatic
Cholangiocarcinoma of the Gallbladder
Cholangiocarcinoma Advanced

Interventions: Drug: nal-IRI
Drug: 5-FU
Drug: leucovorin

First Posted Date: 2017-02-06

Last Posted Date: 2022-05-18

Lead Sponsor: AIO-Studien-gGmbH

Target Recruit Count: 100

Registration Number: NCT03043547

Locations: 🇩🇪
Klinik für Gastroenterologie, Hepatologie und Endokrinologie, Medizinische Hochschule Hannover, Hannover, Germany

mFOLFOX6 vs. mFOLFOX6 + Aflibercept as Neoadjuvant Treatment in MRI-defined T3-rectal Cancer

Phase 2

Completed

Conditions: Rectal Cancer
Rectosigmoid Cancer

Interventions: Drug: Oxaliplatin
Drug: 5-FU
Drug: Leucovorin
Biological: Aflibercept

First Posted Date: 2017-02-06

Last Posted Date: 2023-02-06

Lead Sponsor: AIO-Studien-gGmbH

Target Recruit Count: 119

Registration Number: NCT03043729

Locations: 🇩🇪
Tagestherapiezentrum am ITM & III. Med. Klinik, Mannheim, Germany

Outpatient Performed Pterygium Surgery Study

Phase 4

Withdrawn

Conditions: Pterygium of Conjunctiva and Cornea

Interventions: Drug: Normal saline
Drug: Bevacizumab
Drug: 5-Fluorouracil

First Posted Date: 2017-01-31

Last Posted Date: 2021-08-12

Lead Sponsor: University of California, San Francisco

Registration Number: NCT03037736

Induction Chemotherapy in Young Patients With Locoregionally Advanced Nasopharyngeal Carcinoma

Phase 2

Conditions: Children
Nasopharyngeal Carcinoma

Interventions: Drug: Paclitaxel liposome
Drug: Cisplatin
Drug: 5-fu
Radiation: Radical radiotherapy

First Posted Date: 2017-01-13

Last Posted Date: 2019-08-07

Lead Sponsor: Sun Yat-sen University

Target Recruit Count: 37

Registration Number: NCT03020329

Locations: 🇨🇳
Sun Yat-sen University, Guangzhou, Guangdong, China

Study of IMM 101 in Combination With Standard of Care in Patients With Metastatic or Unresectable Cancer

Phase 1

Terminated

Conditions: Metastatic Cancer

Interventions: Biological: IMM-101
Drug: Gemcitabine
Drug: Folinic Acid
Biological: Anti-PD1
Biological: Ipilimumab
Drug: Cyclophosphamide
Drug: Nab-paclitaxel
Drug: Capecitabine
Drug: Fluorouracil
Drug: Irinotecan
Drug: Oxaliplatin
Biological: cetuximab

First Posted Date: 2017-01-04

Last Posted Date: 2024-11-25

Lead Sponsor: Immodulon Therapeutics Ltd

Target Recruit Count: 2

Registration Number: NCT03009058

Locations: 🇫🇷
Centre Léon Bérard, Dpt Medecine & INSERM, Lyon, France
🇫🇷
Gustave Roussy Cancer Center, Villejuif, France
🇬🇧
St George's University of London, Institute of Infection and Immunity, London, United Kingdom

and more 1 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy